Organoselenium Small Molecules and Chromium(III) Complexes for Intervention in Chronic Low-grade Inflammation and Type 2 Diabetes

Author(s): Jun Zhou, Huibi Xu, Kaixun Huang

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 8 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


There is growing evidence to suggest that chronic, low-grade inflammation occurs in abdominal obesity, insulin resistance, type 2 diabetes mellitus and related complications, and that proinflammatory cytokines play an important role in the onset and progression of type 2 diabetes. These findings consequently provide new opportunities for the use of anti-inflammatory strategies to correct the metabolic disorders. Discovery of new synthetic bioactive small molecules to interfere with chronic, low-grade inflammation and type 2 diabetes has attracted considerable attention in medicinal chemistry. To date, a number of organoselenium small molecules and chromium(III) complexes have been shown to have the potential to alleviate chronic low-grade inflammation and type 2 diabetes, including ebselen, selenomethionine, chromium picolinate, chromium dinicocysteinate, chromium phenylalaninate, trinuclear chromium propionate, chromium histidinate, chromium nicotinate, etc. Here, we review recent advances in development of organoselenium small molecules and chromium(III) complexes to intervene in chronic low-grade inflammation and type 2 diabetes, and discuss their mode of action, potential molecular mechanisms and toxicity.

Keywords: Chromium, Diabetes, Ebselen, Inflammation, Insulin resistance, Pancreatic β-cells, Selenium.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 11 November, 2015
Page: [823 - 834]
Pages: 12
DOI: 10.2174/1568026615666150827094815
Price: $65

Article Metrics

PDF: 54
PRC: 1